CD8α Structural Domains Enhance GUCY2C CAR-T Cell Efficacy.

Area of Science:

• Immunology
• Cancer Biology
• Biotechnology

Background:

• CAR-T cell therapy shows promise for hematological malignancies but faces challenges in solid tumors.
• Tumor microenvironment, poor persistence, and antigen scarcity limit CAR-T efficacy in solid tumors.
• CAR components, particularly hinge and transmembrane domains, are understudied regarding their impact on CAR-T cell function.

Purpose of the Study:

• To compare the impact of CD8ɑ- and CD28-derived hinge and transmembrane domains in GUCY2C-targeted CAR-T cells for colorectal cancer.
• To investigate how structural CAR components influence CAR-T cell affinity, effector function, and in vivo anti-tumor efficacy.

Main Methods:

• Designed third-generation CAR-T cells targeting GUCY2C with either CD8ɑ or CD28 hinge and transmembrane domains.
• Assessed CAR expression, differentiation, exhaustion phenotypes, GUCY2C binding affinity, cytokine production, and cytolytic activity.
• Evaluated in vivo anti-tumor efficacy in a colorectal cancer model.

Main Results:

• CD8ɑ and CD28 domains did not affect CAR expression or T cell phenotypes in antigen-independent contexts.
• CAR-T cells with CD8ɑ structural domains exhibited higher affinity for GUCY2C.
• Enhanced production of inflammatory cytokines and granzyme B, improved cytolytic function against low-antigen tumors, and robust in vivo anti-tumor activity were observed with CD8ɑ CARs.

Conclusions:

• CD8ɑ hinge and transmembrane domains can enhance CAR-T cell affinity and effector functions.
• These structural components are critical for optimizing CAR-T cell therapy in solid tumors like colorectal cancer.
• Consideration of CD8ɑ structural domains in CAR design may lead to more effective CAR-T cell therapies for solid tumors.